Novo Nordisk hires former Director General of DMA

Now-former Director General of the Danish Medicines Agency (DMA) Thomas Senderovitz will soon be spending his time at Novo Nordisk examining large amounts of data coming from the firm's clinical trials.

Photo: Stine Tidsvilde

When the now-former Director General of the Danish Medicines Agency (DMA) Thomas Senderovitz steps into his new role at Novo Nordisk in May, his main focus area will be clinical development, according to an email sent from Novo Nordisk to MedWatch.

"I'm pleased to have Thomas Senderovitz take on the position of senior vice president for Data Science at Novo Nordisk starting mid-May. The Data Science area is for example responsible for handling, analyzing and applying large amounts of data from Novo Nordisk's clinical trials," writes Novo Nordisk Development Executive Vice President Martin Holst Lange in the email.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs